Sagimet Biosciences

SAGIMET BIOSCIENCES INC-A

Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.

Wall Street

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

MURA

PDYN

SCLX

SGMT

VITL

This Vital Farms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Intel, Cleanspark, Super Micro Computer, Upstart, Tesla: Why These 5 Stocks Are On Investors' Radars Today

Movers

AKTS

ATCH

BTCT

EWTX

FUFU

IPHA

KPTI

KTOS

LAES

PRTC

RDZN

SIDU

SMCI

STEC

TNXP

UBXG

XXII

Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket

Nvidia Corporation (NVDA)

NVDA

VEON

This Nvidia Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Sagimet Biosciences Inc. - Series A Common Stock

Sagimet Biosciences Inc

Press Releases

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

Earnings

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

Sagimet Biosciences Announces Oral Presentation at the 9th Annual MASH-TAG 2025 Conference

Health Care

Sagimet Biosciences Announces Oral Presentation at the MASH Pathogenesis and Therapeutic Approaches Keystone Symposium

Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne

Sagimet Biosciences Reports Full Year 2024 Financial Results and Provides Corporate Updates

Sagimet Biosciences Announces Upcoming Presentations at EASL Congress 2025

Sagimet Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Agenus

Alector

Assembly Biosciences, Inc. - Common Stock

Assembly Biosciences

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

C4 Therapeutics

Coya Therapeutics

Editas Medicine

Enanta Pharmaceuticals, Inc. - Common Stock

Enanta Pharma

EXoZymes

Fate Therapeutics

HilleVax

Immunic

Ironwood Pharmaceuticals, Inc. - Class A Common Stock

Ironwood Pharmaceuticals

Kyverna Therapeutics, Inc. - Common Stock

Kyverna Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lyell Immunopharma

Macrogenics

ProKidney Corp. - Class A Ordinary Shares

ProKidney

RAPT Therapeutics

Sangamo Therapeutics, Inc. - Common Stock

Sangamo Therapeutics

Instil Bio

Vigil Neuroscience

Vaxart

HC Wainwright & Co.

Jones Trading

Oppenheimer

JMP Securities

Comments

Sagimet Biosciences

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell